Our Board

  • David Redfern

    Chairman

  • Dr Dominique Limet

    CEO

  • Doug Giordano

  • Dr Zhi Hong

  • Abbas Hussain

  • Dr John Keller

  • Dr Rod MacKenzie

  • Ian McCubbin

  • Ian Tomlinson

  • James Shannon

 
  • David Redfern

    Chairman

    David Redfern is the Chairman of ViiV Healthcare’s Board. David was appointed as GSK’s Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities, strategic planning and dermatology. He is a member of the GSK Corporate Executive Team. Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and Switzerland. David also had overall responsibility for the European HIV business from 2006 to 2008.

    David joined the company in 1994 from PricewaterhouseCoopers, where he managed a portfolio of audit clients and corporate transactions. He began his career with GSK as Corporate Accounts Manager, and spent 4 years in the Corporate Development team before being appointed Finance Director of European Pharmaceuticals in 1999. He was appointed Senior Vice President & Area Director, Central Europe in 2003, where he successfully led the Central Europe markets through their transition into the EU, and Northern Europe in 2005.

    David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

  • Dr Dominique Limet

    CEO

    Our CEO is Dr Dominique Limet, former Senior Vice President (SVP) and Head of Personalised Medicine Strategy for GSK.

    Dominique worked for Ciba-Geigy before joining Glaxo Wellcome in France in 1996. He became Chairman and Managing Director in 2000 and, subsequently, General Manager of GSK France. In 2003 he was appointed SVP and Area Director for GSK's pharmaceutical business in Southern & Eastern Europe.

    Dominique holds a Doctorate in Medicine, a specialisation in occupational medicine, and Marketing and Management qualifications earned at INSEAD. At GSK, Dominique served as a member of GSK's Positive Action Steering Committee and was a board member of the GSK France Foundation, which supported a range of HIV/AIDS-related programmes around the world.

  • Doug Giordano

    Doug Giordano is currently a Senior Vice President in Pfizer’s Worldwide Business Development Group, responsible for leading the evaluation, negotiation and execution of product licensing, partnerships and M&A transactions.  Over the past six years, Doug has led teams responsible for Pfizer acquisitions and product licensing transactions including Pfizer’s acquisitions of Wyeth, Icagen, Excaliard, King Pharmaceuticals, FoldRx, Coley, CovX, Encysive and Serenex, and product collaborations announced with various partners including Hisun, Mylan, GlycoMimetics, Bausch & Lomb and Teuto.

    Before joining Pfizer’s Worldwide Business Development group in 2007, Doug held positions of increasing responsibility within Pfizer’s US Pharmaceuticals commercial strategy and business development team.  Doug has been a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard andPfizer Helpful Answers programs.   

    Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group -- playing a key role in Pfizer’s acquisitions, technology licensing and divestiture activity within medtech.  Prior to his role with the Medical Technology Group, Doug held positions within Pfizer’s US Pharmaceutical Group in finance and global manufacturing.

    Prior to joining Pfizer, Doug was a consultant at Booz, Allen & Hamilton.

    Doug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University’s Johnson School of Business. 

  • Dr Zhi Hong

    Dr Zhi Hong is SVP and Head of the Infectious Diseases Centre of Excellence for Drug Discovery at GSK.

    Prior to joining GSK in 2007, he was Executive Vice President and Chief Scientific Officer of Ardea Biosciences, Inc., a biopharmaceutical company focused on small-molecule drugs to treat viral diseases, cancer and inflammation.

    An inventor on numerous patents and an author of more than 100 research papers, Zhi received his bachelor's degree in Biochemistry from Fudan University in Shanghai and his PhD in Biochemistry from the State University of New York at Buffalo.

  • Abbas Hussain

    Abbas Hussain is President, Emerging Markets at GSK. He joined from Eli Lilly and Company, where he was President, Europe.

    Abbas joined Lilly UK in 1988 before moving to Australia in 1990. Over the following 12 years, he held senior positions for the company in the US, Asia, India, Turkey and Germany. He was appointed European Mid-Size Area Director in 2003 and then Vice President of Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions.

    Abbas has a degree in Medicinal Chemistry & Pharmacology from Loughborough University of Technology, UK.

  • Dr John Keller

    Dr John Keller joined Shionogi Inc. in July of 2010 and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011.

    Immediately prior to joining Shionogi, John was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, John served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, John had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements originally establishing the Shionogi-GSK (later Shionogi-ViiV Healthcare) joint venture. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.

    John holds a Ph.D. in microbiology from Rutgers University and a Bachelors degree in biology from Johns Hopkins University.

  • Dr Rod MacKenzie

    Dr. Rod MacKenzie is Senior Vice President, Head of Pfizer PharmaTherapeutics Research and Development. He oversees an international network of scientists and other pharmaceutical R&D professionals in Research, Pharmaceutical Sciences, Asia R&D, and their functional lines.

    Rod began his career at Pfizer in 1986 as a Research Scientist and worked in many medicinal chemistry programs across various therapeutic areas. Rod is the co-inventor of darifenacin (EnablexTM). He has held a range of posts in the following years, including Senior Vice President, Drug Safety R&D and Comparative Medicine, and Senior Vice President, Head of Worldwide Research.

    Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition.

  • Ian McCubbin

    Ian McCubbin is SVP of Strategy, Logistics and External Supply at GSK.

    He joined GSK's manufacturing and supply business in 1985 and over 16 years held a number of senior production, logistics and continuous improvement roles including Site Director at the Ware manufacturing site in the UK. Ian re-joined GSK in 2006, having held senior operational roles in both Merck Generics and IVAX.

    Ian holds a degree in Pharmacy from Heriot-Watt University, Edinburgh.

  • Ian Tomlinson

    Ian Tomlinson is Senior Vice President and Head of Worldwide Business Development and Biopharmaceuticals R&D at GSK.

    Ian started his career at the MRC Laboratory of Molecular Biology in Cambridge, where he initially worked on the completion of the sequencing and mapping of all human antibody genes, and latterly on engineering recombinant antibodies.

    In 2000, together with Sir Gregory Winter, he co-founded Domantis Limited to develop an entirely new class of drugs based on the smallest fragments of antibodies, called Domain Antibodies, or “dAbs”. As an independent company, Domantis raised $83 million from a range of investors, including Peptech Limited, 3i and Novo Nordisk, hired 80 employees (73 in the UK) and established a state-of-the-art R&D facility before acquisition in 2007 by GSK for $454M, making it one of the largest ever acquisitions of a private biotech company.

    Ian graduated from Trinity College, Cambridge, UK.

  • James Shannon

    James Shannon is GlaxoSmithKline’s Chief Medical Officer (CMO) and as such leads all medical functions within GSK including Clinical Safety and Pharmacovigilance, Medical Affairs, and Medical Policy.

    James, who is trained in medicine and cardiology, has more than 20 years experience at senior levels of the pharmaceutical industry. Most recently, he was Global Head of Drug Development for Novartis Pharma AG before joining GSK in 2012. He has served on the boards of a number of companies including Biotie Therapies, Circassia Holdings Ltd., Crucell, Endocyte Inc, Mannkind Corporation and Xanodyne Pharmaceuticals, Inc..

    He entered the pharmaceutical industry in 1987 by joining Sterling Winthrop, where he worked in Europe, and later in the US. James rose to the position of Senior Vice-President, Clinical Development, before joining Sandoz as Head of Drug Regulatory Affairs in 1995. During the merger of Ciba and Sandoz, he oversaw the creation of the R&D organization for Novartis.

    James received his undergraduate and post graduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK).